BlackRock Fund Advisors’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

BlackRock Fund Advisors’s Portfolio KBIO Stock Details KBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-16,396	Closed	-$64K	–	4007
2015 Q1	$64K	Buy	16,396 +8,641	+111%	+$38.8K	﹤0.01%	3674
2014 Q4	$107K	Buy	7,755 +4,140	+115%	+$59.1K	﹤0.01%	3613
2014 Q3	$45K	Sell	3,615 -263	-7%	-$3.63K	﹤0.01%	3718
2014 Q2	$71K	Sell	3,878 -36,693	-90%	-$628K	﹤0.01%	3657
2014 Q1	$880K	Buy	40,571 +1,124	+3%	+$32.6K	﹤0.01%	3199
2013 Q4	$1.4M	Buy	39,447 +7,700	+24%	+$258K	﹤0.01%	3173
2013 Q3	$1.15M	Buy	31,747 +3,702	+13%	+$169K	﹤0.01%	3170
2013 Q2	$1.27M	Buy	+28,045	New	+$1.27M	﹤0.01%	3139

Other funds holding KBIO

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

BlackRock Fund Advisors's KBIO Position: Q2 2015 in Review

BlackRock Fund Advisors sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q2 2015, closing a stake of 16,396 shares — an estimated $64K sold.

BlackRock Fund Advisors first reported a position in KBIO in Q2 2013 and held it in 8 quarters. The position peaked at $1.4M in Q4 2013. 19 funds tracked by Wall St. Rank hold KBIO as of Q2 2015.

BlackRock Fund Advisors reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q2 2015 after selling out during the quarter.
BlackRock Fund Advisors sold 16,396 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q2 2015, an estimated $64K.
BlackRock Fund Advisors first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 8 quarters.
BlackRock Fund Advisors's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $1.4M in Q4 2013.
19 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q2 2015.

Based on BlackRock Fund Advisors's 13F filing for Q2 2015, filed 7 Aug 2015.